Innovent enters into exclusive global license agreement with Roche for novel DLL3 Antibody Drug Conjugate

CAR-T Digest - August 2020

02 Jan 2025: Innovent enters into exclusive global license agreement with Roche for novel DLL3 Antibody Drug Conjugate

Innovent Biologics has entered into a collaboration and exclusive license agreement with Roche to advance the development of IBI3009, a novel DLL3-targeted ADC candidate for small cell lung cancer
IBI3009 has already received IND approvals in Australia, China, and the U.S., and the first patient for the Phase 1 study was dosed in December 2024. The collaboration aims to develop innovative treatments for advanced small cell lung cancer
IBI3009 targets DLL3, a protein overexpressed in small-cell lung cancer and neuroendocrine tumors, while having low expression in normal tissues. It was developed using Innovent’s proprietary TOPO1i platform and has shown promising anti-tumor activity in preclinical models, especially in chemo-resistant tumors
Innovent will receive an upfront payment of $80 million from Roche and is eligible for up to $1 billion in development and commercial milestone payments, along with tiered royalties on net sales of IBI3009